PostowMAHellmannMD. Adverse events associated with immune checkpoint blockade. N Engl J Med2018; 378(12): 1163–1165.
2.
Abdel-WahabNShahMLopez-OlivoMA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann Intern Med2018; 169(2): 133–134.
3.
BarbosaNSWetterDAWielandCN, et al. Scleroderma induced by pembrolizumab: a case series. Mayo Clin Proc2017; 92(7): 1158–1163.
4.
JoshiMNWhitelawBCPalomarMT, et al. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf)2016; 85(3): 331–339.
5.
RichterMDPinkstonOKottschadeLA, et al. Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience. Arthritis Rheumatol2018; 70(3): 356–360.
Alegre-SánchezAFonda-PascualPSaceda-CorraloD, et al. Relapse of morphea during Nivolumab therapy for lung adenocarcinoma. Actas Dermosifiliogr2017; 108(1): 69–70.
8.
TjarksBJKerkvlietAMJassimAD, et al. Scleroderma-like skin changes induced by checkpoint inhibitor therapy. J Cutan Pathol2018; 45(8): 615–618.
9.
ChoMNonomuraYKakuY, et al. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma. J Dermatol2019; 46: e43–e44.
